Medicx Fund Regulatory News (MXF)

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, REPUBLIC OF IRELAND, REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR JAPAN

MedicX Fund Limited

("MedicX Fund", the "Fund" or the "Company")

Prospectus Published

The board of directors of MedicX Fund (LSE: MXF), the specialist primary care infrastructure investor in modern purpose-built primary healthcare properties in the United Kingdom, is pleased to announce that the prospectus relating to the Company's proposed Placing, Open Offer and Offer for Subscription has been published today.

Copies of the prospectus may, subject to any applicable law, be obtained at no cost at the registered office of the Company or from Collins Stewart Europe Limited.

For further information please contact:

MedicX Group: +44 (0) 1483 869 500

Keith Maddin, Chairman

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

MedicX Fund: +44 (0) 1481 723 450

David Staples, Chairman

Collins Stewart Europe Limited: +44 (0) 20 7523 8000

Andrew Zychowski (Corporate)

Stephen Newby (Corporate)

Dominic Waters (Sales)

Neil Brierley (Sales)

Will Barnett (Sales)

Buchanan Communications: +44 (0) 20 7466 5000

Charles Ryland

Suzanne Brocks

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 57 properties.

The Investment Adviser to the Company is MedicX Adviser Ltd, which is authorised and regulated by the Financial Services Authority and is a subsidiary of the MedicX Group. The MedicX Group is a specialist investor, developer and manager of healthcare properties with 30 people operating across the UK.

The Company's website address is www.medicxfund.com. 

This announcement and the information contained herein is restricted and is not for publication, release or distribution in whole or in part in the United States, Japan, Canada, Australia, Republic of South Africa, New Zealand or the Republic of Ireland.

This announcement does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase, any securities of the Company and any purchase of securities of the Company pursuant to any equity issue undertaken by the Company should only be made on the basis of the information contained in the final prospectus published by the Company and any supplement or amendment thereto (the "Prospectus"). A copy of the Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.hemscott.com/nsm.do. Copies of the Prospectus may, subject to any applicable law, be obtained at no cost at the registered office of the Company or Collins Stewart. The Prospectus will supersede all information provided before the date of the Prospectus and any investment decision must be made only on the basis of the information contained therein.

The shares of the Company have not and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state's securities laws, and may not be offered or sold within the United States, unless an exemption from the registration requirements of the U.S. Securities Act is available. There will be no public offering of the Company's shares in the United States. Accordingly, any offer or sale of the Company's shares will only be offered or sold (i) within the United States, only to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act in private placement transactions not involving a public offering, and (ii) outside the United States in offshore transactions in accordance with Regulation S promulgated under the U.S. Securities Act. Any purchaser of shares in the United States will be required to make certain representations and acknowledgments, including without limitation that the purchaser is a "qualified institutional buyer." Prospective purchasers are hereby notified that a seller of the Company's shares may be relying on the exemption from the registration requirements of the U.S. Securities Act provided by Rule 144A thereunder.

The contents of this announcement have been prepared by and are the sole responsibility of the Company. The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

Collins Stewart Europe Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as sponsor to MedicX Fund Limited and is acting for no-one else in connection with the Issue and the contents of this announcement, and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Collins Stewart Europe Limited nor for providing advice in connection with the Issue and the contents of this announcement or any other matter referred to herein. Collins Stewart Europe Limited is not responsible for the contents of this announcement. This does not exclude or limit any responsibilities which Collins Stewart Europe Limited may have under the Financial Services and Markets Act 2000 or the regulatory regime established thereunder.